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With less than 90 diseases covered by approved treat-
ments in Europe for approximately 7,000 rare diseases
described, patients with rare diseases are underserved.
Although western societies attribute value to equality
of access irrespective of an individual’s ability to pay,
affordability of OMPs (Orphan Medicinal Products) has
been the subject of a health policy debate[1]. The debate
is exacerbated by perceived high acquisition costs for
OMPs whereas their budget impact is low [2,3]. It is
essential to address misconceptions about the rare dis-
eases model to understand how to make it sustainable.
OMPs development drives value to patients by providing
access to innovative treatments in untapped diseases. In
France, the relative share of innovative OMPs reimbursed
between 2001 & 2009 was almost twice as high as com-
mon diseases drugs and most of them targeting diseases
with no approved treatment [3].
OMPs budget impact is likely to remain low [2]. A few
drugs with low price ranges represent largest budget
impact of OMPs [4]. Population size to be treated rather
than individual drug prices influences budget impact in
rare diseases.
The development of OMPs is a risky undertaking for
companies that invest in this field. Due to the small
patient population, development timelines on OMPs are
similar to that of other drugs [5]. The conduct of clinical
trials in rare diseases is often more expensive on a per
patient basis. R&D investment must therefore be recov-
ered with lower volume of sales, leading to higher prices
for OMPs than other medicines.
Scientific advances offer new perspectives by making
treatable and curable new important diseases. Policy
makers must reward innovation based upon unmet need
and patient outcome. Technology platforms, franchises
and global reach are three potential levers at company
level to sustain profitable development of OMPs. New
and innovative pricing models based on rational value
assessment and realized by contractual agreements
could address the issue of affordability while taking into
account country differences.
While there are strategic choices that manufacturers
can make to overcome barriers to contribute to public
health goals, there are many other factors that inhibit
effective or optimal access to new treatments that are
beyond industry’s control or influence.
Social, ethical, political considerations must guide
improved access so that all patients can access OMPs in
an equitable manner. Political will is needed to allocate
the necessary funding within health budgets and support a
solid rare diseases public health policy.
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